<code id='4D9E848467'></code><style id='4D9E848467'></style>
    • <acronym id='4D9E848467'></acronym>
      <center id='4D9E848467'><center id='4D9E848467'><tfoot id='4D9E848467'></tfoot></center><abbr id='4D9E848467'><dir id='4D9E848467'><tfoot id='4D9E848467'></tfoot><noframes id='4D9E848467'>

    • <optgroup id='4D9E848467'><strike id='4D9E848467'><sup id='4D9E848467'></sup></strike><code id='4D9E848467'></code></optgroup>
        1. <b id='4D9E848467'><label id='4D9E848467'><select id='4D9E848467'><dt id='4D9E848467'><span id='4D9E848467'></span></dt></select></label></b><u id='4D9E848467'></u>
          <i id='4D9E848467'><strike id='4D9E848467'><tt id='4D9E848467'><pre id='4D9E848467'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:focus    Page View:98
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In